Gilead Sciences' Kite Pharma Deal Has Already Paid for Itself -- for Investors
The year 2021 -- that's when Gilead Sciences (NASDAQ: GILD) thinks its acquisition of Kite Pharma (NASDAQ: KITE) will start to pay off. When Gilead announced plans to buy Kite, the company stated that the deal was expected to be neutral to earnings by year three and accretive after that.
In one sense, though, Gilead's Kite Pharma acquisition has already paid for itself. How? For investors.
Image source: Getty Images.
Source: Fool.com
Sanofi S.A. ADR Stock
€48.40
-1.630%
Sanofi S.A. ADR is currently one of the favorites of our community with 11 Buy predictions and no Sell predictions.
With a target price of 55 € there is a slightly positive potential of 13.64% for Sanofi S.A. ADR compared to the current price of 48.4 €.
